Miraculins Inc. (TSX-V:MOM) announced June 14 that it has been issued a patent by the State Intellectual Property Office of the People’s Republic of China that covers use of a tape stripping device for skin sampling. The issued patent covers elements of the PreVu®Non-Invasive Skin Cholesterol Lab Processed (LP) Test, specifically relating to the LP collection device, which is used to collect the skin samples which are then sent to a central lab for processing and measuring the skin cholesterol values.
“We have global plans for our PreVu Skin Cholesterol technology,” stated Christopher J.Moreau, President and Chief Executive Officer of Miraculins Inc. “This simple to use laboratory based version of the PreVu technology could prove to be very attractive in certain key emerging markets. Miraculins is very enthusiastic about PreVu’s potential risk assessment role in the fight against cardiovascular disease, the world’s leading cause of death and disability.”
The PreVu LP Test non-invasively measures the amount of cholesterol that has been deposited in skin tissues by painlessly and rapidly collecting skin cells from the palm of the hand using a proprietary medical adhesive collection device, which would then be sealed and sent to a laboratory for processing. The sample collection process is easily self-performed, takes fifteen seconds to conduct and does not require fasting. The PreVu LP Test is Miraculins’ second format of its innovative PreVu Non-Invasive Cholesterol Test technology and is being developed as part of a broader commercialization strategy. In Canada, the final development and commercialization of the LP Test is partnered with Gamma-Dynacare Medical Laboratories, one of Canada’s largest and most respected medical laboratories.
Miraculins recently announced the Notice of Allowance for a U.S. patent providing coverage on its PreVu Point of Care Test format, and the launch of a new English Canadian website for PreVu (www.prevu.com).